About NDR

NDR is a Multiple Sclerosis (MS) Research & Development company. At NDR, we perform molecular and cell-biological research on cultured human 3D minibrains (oligocortical spheroids with multiple brain cell types derived from a human embryonic stem cell line). We are developing this model to validate ‘druggable’ targets derived from our big-data molecular landscape of MS. We investigate the effects of genetic manipulation (CRISPR-cas on key MS genes/proteins) as well as of compounds that activate or inhibit targeted functioning of the (MS) minibrains to gain new mechanistic insights into the disease. We aim to develop disease-modifying drugs for MS that will eventually be tested in clinical trials.